 Context Therapeutics Inc NASDAQ: CNTX posted data from the window-of-opportunity trial of onapristone extended-release ONA-XR in postmenopausal patients with progesterone receptor-positive PR early breast cancer. The data were presented at San Antonio Breast Cancer Symposium. 